SCHEMBL1689206

SCHEMBL1689206

O=C(CC(=O)Nc1ccccc1)Nc1ccccc1

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EPHX2 P34913 2/20 0.68
HDAC4 P56524 4/20 0.68
HDAC1 Q13547 4/20 0.68
HDAC7 Q8WUI4 4/20 0.68
HDAC11 Q96DB2 4/20 0.68
HDAC8 Q9BY41 4/20 0.68
HDAC6 Q9UBN7 4/20 0.68
HDAC9 Q9UKV0 4/20 0.68
HDAC5 Q9UQL6 4/20 0.68
HDAC3 O15379 3/20 0.68
HDAC2 Q92769 3/20 0.68
HDAC10 Q969S8 3/20 0.68
KDM1A O60341 1/20 0.67
MAPT P10636 3/20 0.64
TP53 P04637 1/20 0.64
EPHX1 P07099 1/20 0.64
TSHR P16473 1/20 0.64
CDK9 P50750 1/20 0.64
SMN1; SMN2 Q16637 1/20 0.64
CLK4 Q9HAZ1 1/20 0.64

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9235727 0.93 HDAC4 (0.61) EPHX2HDAC4HDAC1HDAC7HDAC11
SCHEMBL8089206 0.91 HDAC4 (0.67) EPHX2HDAC4HDAC1HDAC7HDAC11
SCHEMBL27538195 0.90 EPHX2 (0.63) EPHX2HDAC4HDAC1HDAC7HDAC11
SCHEMBL175602 0.90 EPHX2 (0.63) EPHX2HDAC4HDAC1HDAC7HDAC11
SCHEMBL19026741 0.89 HDAC4 (0.58) EPHX2HDAC4HDAC1HDAC7HDAC11
SCHEMBL19026946 0.89 L3MBTL1 (0.75) EPHX2HDAC4HDAC1HDAC7HDAC11
SCHEMBL307290 0.89 KMT2A (0.61) EPHX2HDAC4HDAC1HDAC7HDAC11
SCHEMBL3342586 0.87 L3MBTL1 (0.80) EPHX2HDAC4HDAC1HDAC7HDAC11
SCHEMBL14964154 0.86 EPHX2 (0.59) EPHX2HDAC4HDAC1HDAC7HDAC11
SCHEMBL3021545 0.86 MAPT (0.67) EPHX2HDAC4HDAC1HDAC7HDAC11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 105 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116693529-A Synthesis method of 2-aza [2.2.2] octane compound 河南师范大学 2023-09-05 CN claimed
CN-116425904-A Supported Ziegler-Natta catalyst and preparation method and application thereof 山东京博石油化工有限公司 2023-07-14 CN claimed
CN-111463445-B Modified carbon material, all-vanadium redox flow battery, and preparation method and application thereof 上海电气集团股份有限公司 2022-05-06 CN claimed
CN-114195671-A Asymmetric malonanilide compound and synthesis method thereof 河南师范大学 2022-03-18 CN claimed
EP-1896395-A2 MODIFIED MALONATE DERIVATIVES Merck & Co., Inc. (US) 2008-03-12 EP claimed
WO-2007002248-A2 MODIFIED MALONATE DERIVATIVES MERCK & CO., INC. (US) 2007-01-04 WO claimed
US-6780887-B1 TREATING AND/OR PREVENTING ISCHEMIA, PATHOLOGIES ASSOCIATED WITH ISCHEMIA OR PATHOLOGIES ASSOCIATED WITH MITOCHONDRIAL DEFICIENCIES SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) 2004-08-24 US claimed
US-20020049190-A1 Pharmaceutical compositions comprising metal complexes ANORMED INC. (CA) 2002-04-25 US claimed
EP-1163247-A1 PHARMACEUTICAL COMPOSITIONS COMPRISING METAL COMPLEXES ANORMED INC. (CA) 2001-12-19 EP claimed
EP-1092432-A1 Anti-ischemic compounds SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES S.A. (S.C.R.A.S.) (FR) 2001-04-18 EP claimed
WO-2000056743-A1 PHARMACEUTICAL COMPOSITIONS COMPRISING METAL COMPLEXES ANORMED INC. (CA) 2000-09-28 WO claimed
EP-0512211-B1 Process for the preparation of substituted malonic ester anilides and malonic acid monoanilides HUELS CHEMISCHE WERKE AG (DE) 1995-04-12 EP claimed
US-5334747-A Reacting substituted malonic acid dialkyl ester with aniline in presence of stoichiometric amount of alkali alcoholate, neutralizing product with acid, saponifying with water HULS AKTIENGESELLSCHAFT (DE) 1994-08-02 US claimed
JP-2250053-A None JP disclosed
US-12427798-B2 Heat-sensitive recording composition NIPPON KAYAKU KABUSHIKI KAISHA (JP) 2025-09-30 US disclosed
US-20250001788-A1 HEAT-SENSITIVE RECORDING COMPOSITION NIPPON KAYAKU KABUSHIKI KAISHA (JP) 2025-01-02 US disclosed
EP-0029719-A1 Vulcanizable rubber compositions inhibited from premature vulcanization by methylene thioethers, and novel methylene thioethers MONSANTO COMPANY (US) 1981-06-03 EP disclosed
US-4271050-A Vulcanizable rubber compositions inhibited from premature vulcanization by methylene thioethers MONSANTO COMPANY (US) 1981-06-02 US disclosed
EP-0012112-A1 Pressure-sensitive or heat-sensitive recording material CIBA-GEIGY AG (CH) 1980-06-11 EP disclosed
US-3932182-A An organic photoconductive composition comprising an organic photoconductive compound and a sensitizing compound having an active methylene group MITSUBISHI PAPER MILLS, LTD. (JA) 1976-01-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020049190-A1 Pharmaceutical compositions comprising metal complexes CFD, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, F12 EPHX2 1014/4885HDAC4 2477/4885HDAC1 1744/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.